<DOC>
	<DOCNO>NCT01091168</DOCNO>
	<brief_summary>In metastatic breast cancer ( MBC ) patient already receive anthracyclines , taxanes , antimetabolites vinca-alkaloids developed drug resistance drug , therapeutic option limit . Alkylating agent show modest activity pretreated metastatic breast cancer . This phase III trial compare effectiveness safety profile vinflunine alkylating agent physician choice MBC patient exhaust anthracyclines , taxanes , antimetabolites vinca-alkaloids .</brief_summary>
	<brief_title>Trial Vinflunine Versus Alkylating Agent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>( main condition ) Female patient 18 75 year age metastatic breast cancer histologically/cytologically confirm amenable curative surgery radiotherapy receive least two prior chemotherapy regimen include anthracyclines , taxanes , antimetabolite vincaalkaloid longer candidate drug , Karnofsky performance score least 70 % , adequate haematological , hepatic renal function ECG without clinically relevant abnormality . Concurrent serious uncontrolled medical disorder , know clinical evidence brain metastasis leptomeningeal involvement , pulmonary lymphangitis symptomatic pleural effusion symptomatic ascites , history second primary malignancy , HIV infection , preexist neuropathy , pregnancy breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>